Custom-made “nag” eye plaques for 125i brachytherapy

Nag, Subir; Wang, Dian; Wu, Hong; Bauer, Cary B.; Chambers, Robert B.; Davidorf, Frederick H.

doi:10.1016/s0360-3016(03)00324-9

Cited by 25 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other plaque designs, as the COMS plaque and the OSU-Nag plaque, displace the seeds to maintain a certain distance to sclera, to reduce the sclera dose and the tumor dose gradient (2,15). The protruding sources of the St. Erik plaque make the position of the plaque relative to the sclera uncertain.…”

Section: Discussionmentioning

confidence: 99%

“…125 I seeds, the dose reduction is on the order of 13-14% at 10 mm depth from inner sclera, compared to TG-43 conditions (11,14). Another plaque design, the OSU-NAG plaque, has similarities with the St. Erik plaque in that the seeds are manually glued instead of being positioned in a seed carrier (as for COMS plaques) (15,16). They differ, however, in that the OSU-NAG plaque displaces the seeds 2 mm from sclera to avoid high dose regions and to reduce the tumor dose gradient.…”

Section: The Collaborative Ocular Melanoma Study (Coms) Was Initiatedmentioning

confidence: 99%

See 1 more Smart Citation

Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for 125I brachytherapy

et al. 2014

View full text Add to dashboard Cite

1 AbstractPurpose: At St. Erik Eye Hospital in Stockholm, ocular tumors of apical height >6 mm are treated with brachytherapy, using 125 I seeds attached to a gold alloy plaque while the treatment planning is performed assuming homogeneous water surroundings. The aim of this work was to investigate the dose modifying effects of the plaque and the seed fixating silicone rubber glue. Methods and materials:The impact of the gold plaque and the silicone rubber glue was studied with the Monte Carlo code MCNP5. Results:For the 2 cm most proximal to the plaque surface along the plaque central axis, the eyeball received 104.6% -93.0% of the dose in all-water conditions.Conclusions: The 0.3 mm thick layer of silicone rubber glue, used for seed fixation, attenuates photons little enough to allow characteristic X-rays from the gold alloy-plaque to reach the eyeball. Close to the plaque, the dose rates were higher with the plaque and glue present, than in homogeneous water conditions. This is in contrast to what has been reported for more commonly used eye plaques, demonstrating the importance of investigating the dosimetry of individual treatment systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Collaborative Ocular Melanoma Study (Coms) Was Initiatedmentioning

confidence: 99%

Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for 125I brachytherapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The customized plaques allowed for more conformal tumor coverage for irregular (i.e., non-circular) lesions, improved the dose conformity and distribution for peripapillary tumors, and irradiated a smaller area of normal retina. 15 …”

Section: Introductionmentioning

confidence: 99%

Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

Objective To report our experience in long-term follow-up of ocular melanoma patients treated with custom OSU-Nag eye plaques utilizing 125I sources. Methods A retrospective chart review was conducted for 113 consecutive ocular melanoma patients with follow-up visual acuity data who were treated with OSU-Nag plaque episcleral brachytherapy at The Ohio State University Medical Center from 1994 to 2009. Visual acuity, complication data, and recurrence rates were recorded up to 120 months post-brachytherapy. Results Median age at presentation was 63.0 years (range 22–93). Median follow-up was 65.5 months (range 2–180). Median radiation dose at the prescription point was 85.8 Gy (range 51.8–103.7). Preservation of useful visual acuity, defined as better than 20/200, was noted in 43/74 (58%) of patients in the current study at 36 months compared with 50.1% of COMS participants. By 120 months, 17/30 (57%, 95% CI: 45–69%) progressed to visual acuity worse than 20/200, while 9/30 (30%) retained visual acuity of 20/40 or better, and 4/30 (13%) were 20/50 to 20/200. The rate of retinopathy after radiation was approximately 40% of all those observed by 60 months. Baseline visual acuity, apical tumor height, AJCC tumor category, and distance between the tumor and the fovea were all significantly associated with loss of visual acuity. The local tumor control rate by 60 months of follow-up was 93% (95% CI: 85–97%). Conclusions The OSU-Nag custom 125I plaque is an effective treatment for uveal melanoma, with preservation of useful visual acuity in 58% of eyes 3 years after treatment and 43% of eyes 10 years after treatment.

show abstract

“…Although in principle, any type of eye plaque could be used if the treatment goals could be achieved, the COMS eye plaques have become most popular for both their standardization and convenience. Currently, although other types of eye plaques are available (6,7), the COMS eye plaque design is the most popular type used in eye brachytherapy (8). It is currently available in seven standard sizes, with diameters ranging from 10 to 22 mm in 2-mm increments.…”

Section: Introductionmentioning

confidence: 99%

A comprehensive dosimetric comparison between 131Cs and 125I brachytherapy sources for COMS eye plaque implant

et al. 2010

View full text Add to dashboard Cite

Custom-made “nag” eye plaques for 125i brachytherapy

Cited by 25 publications

References 20 publications

Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for 125I brachytherapy

Monte Carlo dosimetry of the eye plaque design used at the St. Erik Eye Hospital for 125I brachytherapy

Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy

A comprehensive dosimetric comparison between 131Cs and 125I brachytherapy sources for COMS eye plaque implant

Contact Info

Product

Resources

About